HTAC RECOMMENDATION ON THE PNF INCLUSION OF REMDESIVIR FOR ADULT PATIENTS WITH COVID-19 REQUIRING HOSPITALIZATION

HTAC Recommendation on COVID-19 Moderna for children 6 to 11 years old

HTAC Guidance: Limited evidence of improved protection from 2nd booster dose among healthy individuals aged 18-49 years

HTAC Recommendation on CoronaVac COVID-19 Vaccine for children 6 to 17 years old

HTAC recommendation for the inclusion of insulin glargine non-inclusion of insulin detemir for the treatment of type 1 and type 2 diabetes mellitus in the PNF.

[Presentation slides + Question and answers] HTA Philippines Virtual Public Consultation for the Preliminary Priority List for HTA 2022

HTAC’S PRELIMINARY LIST OF PRIORITY TOPICS FOR HTA 2022 UNDER THE GENERAL TRACK

HTAC recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma

HTAC Recommendation on the Second Booster of COVID-19 vaccines for the prevention of COVID-19 among individuals aged 50 years old and older and individuals with comorbidities aged 18 to 49 years old

HTAC Guidance: Self-Administered Antigen Test Kits (SAAgT)